Literature DB >> 23844693

Probenecid: an emerging tool for neuroprotection.

Ana Laura Colín-González1, Abel Santamaría.   

Abstract

Probenecid (PROB) has been widely used for long time for different clinical purposes, from gout treatment to designs as a coadjutant for antibiotic agents. Among its many properties, the ability of PROB to preserve high concentrations of several metabolites and other agents in the CNS, together with its relative lack of side-effects, have made this drug a valuable pharmacological tool for clinical and basic research. Nowadays, biomedical research offers evidence about new targets for PROB that may help to explain its many beneficial actions. In this regard, despite most of its protective actions in the brain have been largely related to its capacity to accumulate the inhibitory metabolite kynurenic acid to further inhibit the glutamate-related excitotoxicity in different animal models of neurological disorders, in this review we describe the basic aspects of PROB's pharmacokinetics and mechanisms of action and discuss other alternative targets recently described for this drug that may complement its pattern of activity in the CNS, including its role as anti-inflammatory and anti-nociceptive agent when targeting different key proteins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23844693     DOI: 10.2174/18715273113129990090

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  3 in total

1.  Influence of Phosphodiesterase Inhibition on CRE- and EGR1-Dependent Transcription in a Mouse Hippocampal Cell Line.

Authors:  Erik Maronde
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

2.  Organic anion transporter 1 is an HDAC4-regulated mediator of nociceptive hypersensitivity in mice.

Authors:  Christian Litke; Anna M Hagenston; Ann-Kristin Kenkel; Eszter Paldy; Jianning Lu; Rohini Kuner; Daniela Mauceri
Journal:  Nat Commun       Date:  2022-02-15       Impact factor: 17.694

3.  Acute Pannexin 1 Blockade Mitigates Early Synaptic Plasticity Defects in a Mouse Model of Alzheimer's Disease.

Authors:  Carolina Flores-Muñoz; Bárbara Gómez; Elena Mery; Paula Mujica; Ivana Gajardo; Claudio Córdova; Daniela Lopez-Espíndola; Claudia Durán-Aniotz; Claudio Hetz; Pablo Muñoz; Arlek M Gonzalez-Jamett; Álvaro O Ardiles
Journal:  Front Cell Neurosci       Date:  2020-03-19       Impact factor: 5.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.